Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

Journal of Immunotherapy

Volumn 26, Issue 4, 2003, Pages 332-342

  Dudley, Mark E ^a   Wunderlich, John R ^a   Shelton, Thomas E ^a   Even, Jos ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cell transfer; Immunotherapy; Melanoma; Tumor antigen; Tumor infiltrating lymphocyte

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER SCREENING; CELL ACTIVITY; CLINICAL PROTOCOL; CLONAL VARIATION; CONTROLLED STUDY; GENETIC EPISTASIS; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYTOKINES; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL;

EID: 0037829421     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200307000-00005     Document Type: Article

References (18)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298:850-854.
2. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86:1159-1166.
3. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992; 257:238-241.
4. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998; 92:1549-1555.
5. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001; 24:363-373.
6. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002; 25:243-51.
7. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99:16168-16173.
8. Dudley ME, Ngo LT, Westwood J, et al. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J Sci Am. 2000; 6:69-77.
9. Pannetier C, Levraud J-P, Lim A, et al. The Immunoscope approach for the analysis of T cell repertoires. In: The Human T Cell Antigen Receptor: Selected Protocols and Applications. (Oksenberg JR, ed), Chapman & Hall, New York, NY 1997:287-325.
10. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180:347-352.
11. Bownds S, Tong-On P, Rosenberg SA, et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother. 2001; 24:1-9.
12. Parkhurst MR, Fitzgerald EB, Southwood S, et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998; 58:4895-4901.
13. Puisieux I, Even J, Pannetier C, et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol. 1994; 153:2807-2818.
14. Yannelli JR, Hyatt C, McConnell S, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer. 1996; 65:413-421.
15. Seiter S, Monsurro V, Nielsen MB, et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother. 2002; 25:252-263.
16. Wei S, Charmley P, Robinson MA, et al. The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics. 1994; 40:27-36.
17. IMGT, the international ImMunoGeneTics information system,:8104, (Initiator and coordinator:; Marie-Paule Lefranc, Montpellier, France), accessed February, 2003.
18. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000; 165:948-955.